Search results | dermatology


Dermatology Partnering Terms and Agreements

The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals

Sensory Organ Partnering Terms and Agreements

The Sensory Organ Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter sensory organ partnering deals.


Dermatology partnering – recent deals analysis 2009-2014

Partnering in the last decade has seen an increase in dermatology with an rise specifically in modern diagnostic technologies.


Dermatology is the collective term used to describe the study of diseases that affect the skin, hair and nails.

Astellas looking to sell dermatology assets in pharma rumor mill

Japan’s big pharma, Astellas, looks to sell dermatology assets according to pharma rumor mill sources.

Nycomed’s US Dermatology business to become an independent entity

Following Takeda’s acquisition of Nycomed, its US dermatology subsidiary has announced it will become an independent entity.

Both, Actavis and Sanofi competing for Omega Pharma

Several companies are rumored to be competing to acquire Omega Pharma, the fastest growing consumer healthcare company in the U.K. and Ireland.

Life Science M&A Deal Trends in Q2, 2014

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

A review of the Top 50 Pharma companies of 2014

The 2014 top 50 Pharma company list is out, with an interesting number of movers and shakers By Alamelu Elango

Sun Pharmaceutical: M&A activity 2009-2014

Sun Pharmaceutical has announced 6 M&A deals since 2009.


Valeant Pharmaceuticals is a top pharmaceutical company based in Montreal, Quebec, Canada

Current Agreements Deal Analysis Update : June 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in May 2014.


Sorry, your search returned no results.


Asset purchase agreement for dermatology product portfolio

Valeant Canada has completed the acquisition of Valeo Pharma’s dermatology product portfolio and several specialty products.

Valeant sells its dermatology products for $1.4 billion

Valeant Pharmaceuticals International has entered into an agreement with Nestle to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash.

Dermira acquires $35 million in Series B financing to boost innovative therapies in dermatology

Dermira has raised $35 million of new funding in a Series B financing and related transaction

Sandoz gains lead in dermatology with Fougera M&A

Sandoz has completed its USD 1.525 billion M&A of specialty US dermatology company Fougera Pharmaceuticals on a cash and debt free basis

Top pharma giant Novartis acquires specialty dermatology company Fougera

Top pharma company, Novartis is buying specialty dermatology generics firm Fougera Pharmaceuticals for $1.525 billion in cash

Sanofi taking bids for dermatology franchise

Dermatology drugs aren’t growing fast enough. At least not in Sanofi-Aventis’ opinion…

Bayer, Kythera ink $373m dermatology deal

Los Angeles-based Kythera Biopharmaceuticals has landed a $373 million licensing deal with Bayer Healthcare’s dermatology unit Intendis. The group gets rights to Kythera’s lead product candidate, ATX-101, outside the U.S. and Canada.

Bayer HealthCare acquires two dermatology product lines from SkinMedica

Both Desonate(R) and NeoBenz(R) Micro are currently marketed in the U.S. by SkinMedica, Inc. Under the transaction, which is still subject to the necessary regulatory approvals, Intendis will acquire all commercial rights, including assigned contracts and intellectual property related to the two product lines. The deal is expected to close in the Fall of 2009.

Cosmederm Bioscience received $50 million investment financing

Cosmederm Bioscience has announced that UK-based Woodford Investment Management is investing $50 million financing into Cosmederm Bioscience.

UCB and Dermira agree an exclusive pharma licensing agreement

UCB and Dermira have entered into an exclusive pharma licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology.